Teva Pharmaceuticals
TEVA
557 hedge funds and large institutions have $13.7B invested in Teva Pharmaceuticals in 2018 Q3 according to their latest regulatory filings, with 79 funds opening new positions, 172 increasing their positions, 170 reducing their positions, and 59 closing their positions.
34% more first-time investments, than exits
New positions opened: 79 | Existing positions closed: 59
3% more funds holding
Funds holding: 540 → 557 (+17)
1% more repeat investments, than reductions
Existing positions increased: 172 | Existing positions reduced: 170
5% less call options, than puts
Call options by funds: $596M | Put options by funds: $625M
2.94% less ownership
Funds ownership: 65.51% → 62.56% (-2.9%)
13% less funds holding in top 10
Funds holding in top 10: 16 → 14 (-2)
15% less capital invested
Capital invested by funds: $16.2B → $13.7B (-$2.5B)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$197M |
| 2 |
Capital World Investors
Los Angeles,
California
|
+$112M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$91M |
| 4 |
BMO
Beck Mack & Oliver
New York
|
+$69.5M |
| 5 |
AllianceBernstein
Nashville,
Tennessee
|
+$53.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NC
Northern Cross
Boston,
Massachusetts
|
-$502M |
| 2 |
HCM
Highfields Capital Management
Boston,
Massachusetts
|
-$303M |
| 3 |
PC
PointState Capital
New York
|
-$162M |
| 4 |
Franklin Resources
San Mateo,
California
|
-$132M |
| 5 |
Millennium Management
New York
|
-$113M |
TEVA Hedge Fund Activity: Q3 2018 in Review
557 of the 4,375 institutional investors tracked by Wall St. Rank reported a position in Teva Pharmaceuticals (TEVA) for Q3 2018, worth a combined $13.7B — down 15% from $16.2B a quarter earlier.
Buyers outnumbered sellers: 79 funds opened new TEVA positions and 59 closed out — a net gain of 20 holders — while 172 added to existing stakes and 170 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $197M. The largest seller was Northern Cross, cutting an estimated $502M.
- 557 institutional investors held Teva Pharmaceuticals (TEVA) as of Q3 2018, up from 540 in Q2 2018.
- Funds reported $13.7B of Teva Pharmaceuticals stock for Q3 2018, down 15% quarter-over-quarter.
- 79 funds opened new Teva Pharmaceuticals positions in Q3 2018 and 59 closed out, a net change of +20 holders.
- The largest Teva Pharmaceuticals buyer in Q3 2018 was Wellington Management Group, an estimated $197M added.
- The largest Teva Pharmaceuticals seller in Q3 2018 was Northern Cross, an estimated $502M sold.
Based on aggregated 13F filings for Q3 2018.